Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Change in Acquisitions & Divestments (2019 - 2025)

C4 Therapeutics (CCCC) has 6 years of Change in Acquisitions & Divestments data on record, last reported at $52.3 million in Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments fell 3.86% year-over-year to $52.3 million; the TTM value through Dec 2025 reached $219.1 million, down 6.07%, while the annual FY2025 figure was $219.1 million, 6.07% down from the prior year.
  • Change in Acquisitions & Divestments reached $52.3 million in Q4 2025 per CCCC's latest filing, up from $51.2 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $115.0 million in Q1 2021 and bottomed at $51.2 million in Q3 2025.
  • Average Change in Acquisitions & Divestments over 5 years is $68.8 million, with a median of $65.6 million recorded in 2022.
  • The widest YoY moves for Change in Acquisitions & Divestments: up 44.85% in 2022, down 37.05% in 2022.
  • A 5-year view of Change in Acquisitions & Divestments shows it stood at $86.1 million in 2021, then fell by 22.12% to $67.1 million in 2022, then rose by 4.35% to $70.0 million in 2023, then dropped by 22.19% to $54.4 million in 2024, then dropped by 3.86% to $52.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Acquisitions & Divestments were $52.3 million in Q4 2025, $51.2 million in Q3 2025, and $60.8 million in Q2 2025.